Skip to main content
Jiangsu Canopus Wisdom Medical Technology Co.,Ltd. logo

Jiangsu Canopus Wisdom Medical Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 301290 ISIN · CNE1000065F2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 531 across all filing types
Latest filing 2026-05-28 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 301290

About Jiangsu Canopus Wisdom Medical Technology Co.,Ltd.

https://www.dx-med.com

Jiangsu Canopus Wisdom Medical Technology Co., Ltd. specializes in the research, development, and manufacturing of advanced medical rehabilitation equipment and intelligent healthcare solutions. The company focuses on integrating artificial intelligence and robotics into clinical practice, offering a portfolio that includes lower-limb rehabilitation robots, upper-limb training systems, and smart nursing beds. These products are designed to assist patients with neurological or musculoskeletal impairments in regaining mobility and independence. By leveraging digital health technologies, the company provides comprehensive systems for gait analysis, functional assessment, and personalized therapy protocols. Its solutions target healthcare providers, specialized rehabilitation centers, and long-term care facilities, aiming to enhance therapeutic outcomes and optimize clinical workflows through technological innovation.

Recent filings

Filing Released Lang Actions
关于部分首次公开发行前已发行股份上市流通提示性公告
Share Issue/Capital Change Classification · 85% confidence The document is a formal exchange announcement by Jiangsu Dongxing Smart Medical Technology Co., Ltd. regarding the lifting of lock-up restrictions and the listing/circulation of pre-IPO restricted shares. It provides detailed capital structure changes (number of shares locked vs unlocked, percentages, new free-float), listing date for the unlocked shares, shareholders affected, and regulatory references. This is not a financial report (10-K, IR, ER, etc.), nor a management change or legal update. Instead, it announces a change in the company’s capital structure (unlocking and listing previously issued shares), which falls under the “Share Issue/Capital Change” category (Code: SHA).
2026-05-28 Chinese
关于重大资产重组的进展公告
M&A Activity Classification · 87% confidence The document is a formal announcement by a listed company (江苏东星智慧医疗科技股份有限公司) providing a progress update on a major asset reorganization (purchase of 90% equity in a target company). It outlines the transaction overview, past and pending approvals, and the draft asset purchase report. This is not a financial report, dividend notice, or management change; it is a corporate action M&A announcement. According to the filing definitions, it best fits “M&A Activity” (Code: TAR).
2026-05-26 Chinese
关于暂不召开股东会的公告
Regulatory Filings Classification · 75% confidence The document is a company announcement regarding the decision to defer the convening of a shareholders’ meeting related to a major asset reorganization. It does not include any financial data or constitute a report itself; it is a regulatory announcement of a corporate action timing change. This falls under the general “Regulatory Filings” category (RNS).
2026-05-12 Chinese
华泰联合证券有限责任公司关于江苏东星智慧医疗科技股份有限公司本次重组信息公布前公司股票价格波动情况的核查意见
M&A Activity Classification · 85% confidence The document is an independent financial advisor’s verification opinion (“核查意见”) on stock price fluctuations prior to the announcement of a proposed asset restructuring (cash acquisition of 90% equity) by Jiangsu Dongxing Smart Medical Technology Co. This type of advisory opinion is part of merger and acquisition disclosures. It is not a full annual, interim, or earnings report, nor merely a regulatory publication notice. Therefore, it falls under M&A Activity (Code: TAR).
2026-05-12 Chinese
关于江苏东星智慧医疗科技股份有限公司内幕信息知情人登记制度的制定和执行情况的核查意见
Regulatory Filings Classification · 78% confidence The document is a legal opinion issued by a law firm regarding the establishment and execution of the company’s insider‐information registration system in connection with a cash acquisition transaction. It does not contain financial statements or earnings data, nor is it an announcement of results or dividends. It is a compliance/legal opinion to be filed with regulators as part of transaction materials. This best fits the general “Regulatory Filings” (RNS) category for miscellaneous compliance documents and legal attachments rather than a specific financial report or announcement.
2026-05-12 Chinese
华泰联合证券有限责任公司在充分尽职调查和内核基础上出具的承诺函
M&A Activity Classification · 85% confidence The document is a commitment letter (“承诺函”) from the independent financial advisor (华泰联合证券) concerning due diligence and internal review for a cash acquisition of 90% equity in Wuhan Yijiabao Biotech. This is directly tied to an M&A transaction (“本次交易”). It is not an earnings release, quarterly report, or regulatory certification per se, but rather a transaction-related advisory commitment. According to the taxonomy, documents related to merger proposals or takeover bids fall under M&A Activity (Code: TAR).
2026-05-12 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.